This page is updated frequently with new Antibodies-related patent applications.
| Targeting of chondroitin sulfate glycans|
The present invention relates to functional binding fragments comprising the minimal binding fragments of var2csa, to antibodies against such binding fragments of var2csa, nucleic acids encoding such fragments of var2csa as well as methods for their production. The invention further relates to conjugates and fusion proteins of var2csa polypeptides including the minimal binding fragments and their use, in particular in the treatment of conditions associated with expression of chondroitin sulfate a (csa), such as an inappropriate expression of chondroitin sulfate a (csa)..
Var2 Pharmaceutical Aps
| Fluorescense-detected assays on microfluidic chips|
An assay unit for carrying-out fluorescence-detected assays on physiological samples comprises a microfluidic chip with a microfluidic system to convey a physiological sample or analyte solution through one or more microfluidic channels arranged on the chip, and a photonic system with two or more rectangular waveguide structures arranged on the chip to guide excitation light in the near ir, visible, or near uv range. The microfluidic channels and the waveguide structures cross each other at a detection site.
One Drop Diagnostics SÀrl
| Biomarkers for endometriosis|
The presence of certain auto antibodies and mirnas indicates that a subject has endometriosis. The auto-antibodies recognise antigens listed in table 1.
Queen Mary University Of London
| Anti-fibulin-3 antibodies and uses thereof|
Embodiments described herein provide anti-fibulin-3 antibodies, recombinant proteins that bind specifically to fibulin-3, compositions and the treatment methods comprising these antibodies and recombinant proteins.. .
The Brigham And Women's Hospital, Inc.
| Nucleic acids encoding human antibodies to sialyl-lewis a|
The present invention provides compositions for the production of an antibody or functional fragment thereof directed against sialyl-lewisa (slea). The compositions of the invention include polynucleotides encoding a heavy chain and/or a light chain variable domain that binds to slea.
Mabvax Therapeutics, Inc.
| Antibody polypeptides that antagonize cd40|
Antibody polypeptides that specifically bind a novel epitope of human cd40 are provided. The antibody polypeptides do not exhibit cd40 agonist activity.
| Antibodies against human csf-1r and uses thereof|
The present invention relates to antibodies against human csf-1r (csf-1r antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.. .
Hoffmann-la Roche Inc.
| Actriia binding agents and uses thereof|
The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to actriia and uses for same.. .
Acceleron Pharma Inc.
| Human antigen binding proteins that bind betta-klotho, fgf receptors and complexes thereof|
The present invention provides compositions and methods relating to or derived from antigen binding proteins activate fgf21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-klotho; (ii) fgfr1c, fgfr2c, fgfr3c or fgfr4; or (iii) a complex comprising β-klotho and one of fgfr1c, fgfr2c, fgfr3c, and fgfr4.
| Insulin-like growth factor 1 receptor -specific antibodies and uses thereof|
The blood-brain barrier (bbb) prevents transport of molecules larger than 500 daltons from blood to brain. Receptor-mediated transcytosis (rmt) facilitates transport across the bbb of specific molecules that bind receptors on brain endothelial cells that form the bbb.
National Research Council Of Canada
Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
The blood-brain barrier (bbb) prevents transport of molecules larger than 500 dal tons from blood to brain. Receptor-mediated transcytosis (rmt) facilitates transport across the bbb of specific molecules that bind receptors on brain endothelial cells that form the bbb.
National Research Council Of Canada
Production of cytotoxic antibody-toxin fusion in eukaryotic algae
Methods and compositions are disclosed to engineer chloroplast comprising heterologous genes encoding target binding domain fused to a eukaryotic toxin and produced within a subcellular organelle, such as a chloroplast. The present disclosure demonstrates that when chloroplasts are used, toxins normally refractive to production in eukaryotic cells may be used to produce recombinant fusion proteins with binding domains that are soluble, properly folded and post-translationally modified, where the multifunctional activity of the fusion protein is intact.
The present disclosure provides compositions and methods relating to antibodies that specifically bind to human erythropoietin. The disclosure provides nucleic acids encoding such antibodies and methods of making and using such antibodies..
Binding proteins against vegf, pdgf, and/or their receptors
Binding proteins that bind one or more of vegf, pdgf and/or their receptors, including antibodies, cdr-grafted antibodies, humanized antibodies, binding fragments, fusion proteins, and bispecific or multispecific proteins thereof are disclosed. Also disclosed are methods of making and using the binding proteins..
Agents, uses and methods for the treatment of synucleinopathy
The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as parkinson's disease (including idiopathic and inherited forms of parkinson's disease), diffuse lewy body disease (dlbd), lewy body variant of alzheimer's disease (lbv), combined alzheimer's and parkinson disease, pure autonomic failure and multiple system atrophy..
H. Lundbeck A/s
Antibodies specific for hyperphosphorylated tau and methods of use thereof
The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (phf) tau (ps396), as well as to methods of using these molecules and their tau binding fragments in the treatment of alzheimer's disease and tauopathies.. .
H. Lundbeck A/s
The invention provides antibodies that specifically bind to transthyretin (ttr). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with ttr accumulation or accumulation of ttr deposits (e.g., ttr amyloidosis).
University Health Network
Antibodies to sericin and methods and kits using same
The present invention relates to antibodies that bind to a polypeptide at an epitope in the amino acid sequence of seq id no: 1 (e.g., a sericin polypeptide). The invention also provides methods and kits using the antibodies of the invention.
Compositions and methods for treating and preventing staphylococcus aureus infections
antibodies having fab regions that specifically bind to staphylococcus aureus protein a are capable of mediating opsinization of staphylococcus aureus bacteria despite their expression of antibody-neutralizing protein a. These antibodies and antigen-binding fragments thereof can be used in methods of treating and/or preventing staphylococcus aureus infections..
Methods and compositions comprising tau oligomers
Tau protein has a causative role in alzheimer's disease and multiple other neurodegenerative disorders exhibiting tau histopathology collectively termed tauopathies. The primary function of tau protein is to facilitate assembly and maintenance of microtubules in neuronal axons.
Materials and methods for producing cleaved, hiv-1 envelop glycoprotein trimers
Expression vectors and mammalian cell lines containing them are described that enable the recombinant production of hiv-1 envelope proteins, including sosip modified gp140 trimers capable of inducing broadly neutralizing antibodies.. .
Anti-notch3 antibodies and antibody-drug conjugates
The present invention provides for anti-notch3 antibodies, anti-notch3 antibody-drug conjugates and methods for preparing and using the same.. .
Conjugates of cysteine engineered antibodies
The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (cba) is covalently linked to the cytotoxic agent through an engineered cys, such as an engineered cys in the heavy chain ch3 domain, at a position corresponds to the eu/ou numbering position 442 (or c442) on an antibody cba. The invention also provides methods of preparing the conjugates of the present invention.
Mper-liposome conjugates and uses thereof
The present invention relates to peptides and compositions suitable for use in inducing anti-hiv-1 antibodies. The compositions comprise hiv-1 gp41 membrane proximal external region (mper) peptide-liposome conjugates for induction of broadly reactive anti-hiv-1 antibodies.
Los Alamos National Security, Llc
Novel treatment method
There is provided according to the invention a method of treating a mammal suffering from or susceptible to an immune reaction to drug treatment comprising the raising of anti-drug antibodies which method comprises (a) ex-vivo treating antigen presenting cells obtained from the mammal with an agent which induces ido in said antigen presenting cells in the presence of said drug or an epitope containing fragment thereof and (b) after ido has been induced in said antigen presenting cells, transferring said cells back to the mammal thereby to establish immune tolerance to the drug.. .
Methods of use for therapeutics targeting the pathogen porphyromonas gingivalis
The invention relates to compositions, formulations, vaccines and antibodies for the prevention and/or treatment of aging and brain disorders, including alzheimer's disease, diabetes, cardiovascular disease, retinal disorders and arthritis. The invention also provides methods of treatment of aging disorders, brain disorders, including alzheimer's disease, diabetes, cardiovascular disease, retinal disorders, and arthritis by administering compositions, formulations, vaccines and antibodies described in the specification.
Use of thiopyrimidinecarboxamide for treating cancer
Alone or in combination with an antineoplastic agent, microtubule affecting agents, antineoplastic agents, anti-angiogenesis agents, vegf receptor kinase inhibitors, antibodies against the vegf receptor, interferon, or radiation.. .
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
The present invention relates to therapeutic immunoconjugates comprising sn-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to egp-1 (trop-2), ceacam5, ceacam6, cd74, cd19, cd20, cd22, csap, hla-dr, afp or muc5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg.
Polyclonal-monoclonal elisa assay for detecting n-terminus pro-bnp
A specific and sensitive in vitro elisa assay and diagnostic test kit is disclosed for determining levels of nt-probnp protein in a variety of bodily fluids, non-limiting examples of which are blood, serum, plasma, urine and the like. The nt-probnp elisa assay test employs the sandwich elisa technique to measure circulating nt-probnp in human plasma.
Nexus Dx, Inc.
Diagnosis of cancer by detecting auto-antibodies against epidermal growth factor (egf)
The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against epidermal growth factor (egf) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an epidermal growth factor receptor inhibitor..
Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43
The invention relates to antibodies, antibody fragments and binding agents that specifically recognize tdp-43 associated with frontotemporal dementia (ftd), but not tdp-43 associated with amyotrophic lateral sclerosis (als) or tdp-43 associated with healthy human brain tissue, and antibodies, antibody fragments and binding agents that specifically recognize tdp-43 associated with als, but not tdp-43 associated ftd or tdp-43 associated with healthy human brain tissue.. .
Arizona Board Of Regents On Behalf Of Arizona State University
Diagnosis of cancer by detecting auto-antibodies against egf-receptor
The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against epidermal growth factor receptor (egfr) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an inhibitor of egfr activity..
Method for assaying soluble gpc3 protein
The present invention relates to a method for assaying soluble gpc3 protein in a test sample, comprising using two different antibodies binding to different epitopes present in the n-terminal region of gpc3 protein.. .
Jsr Life Sciences Corporation
Biomarkers and therapeutic targets for sarcoma
New sarcoma cell surface targets have been identified and include lingo-1, kcnn1 and cdh23. Specific binding agents that specifically bind to these targets include antibodies and aptamers.
Isis Innovation Limited
Predicting response to epigenetic drug therapy
The present invention relates to the field of epigenetics. More specifically, the present invention provides methods and compositions useful for predicting response to epigenetic drug therapy.
The Johns Hopkins University
Glycopeptide and uses thereof
A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof..
University Of Georgia Research Foundation, Inc.
Anti-tissue inhibitor of metalloproteinase-4 (timp-4) antibodies and methods of use thereof
Compositions and methods for treating diseases and disorders expressing tissue inhibitor of metalloproteinase-4 (timp-4) are provided.. .
Lankenau Institute For Medical Research
Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
We provide an antibody capable of binding to an intracellular prl-i or prl-3 polypeptide, in which the antibody is capable of binding to an epitope bound by antibody 269, antibody 223 or antibody 318. Such anti-prl antibodies may be capable of binding to intracellular prl-i or prl-3.
Agency For Science, Technology And Research
Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
The invention provides compositions and methods for treating her2-postitive cancers. The method comprising administering a pd-1 axis binding antagonist and an antibody that targets her2..
Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof
The present disclosure provides light chain polypeptides that include a c-terminal extension, as well as antibodies and antibody conjugates containing such modified light chain polypeptides, where the c-terminal extension includes one or more cysteine residues. Conjugates that include an antibody of the present disclosure conjugated to an agent via the cysteine residue of the c-terminal amino acid extension are also provided.
Antibodies against glioma biomarkers
The present disclosure is directed to antibodies binding to eltdi. Plexin-b2, spondin-1, fibulin-1, lingo i or slit3 and methods of using such antibodies to treat and/or diagnose gliomas.
Oklahoma Medical Research Foundation
Anti-tlr4 antibodies and uses thereof
Disclosed are antibodies that specifically bind toll-like receptor 4 (tlr-4), and to methods of using the anti-tlr4 antibodies as therapeutics and diagnostic agents.. .
Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd28-positive hematological malignancies
The present invention relates to methods of treatment of light chain amyloidosis and other cd38-positive hematological malignancies with anti-cd38 antibodies.. .
Tufts Medical Center, Inc.
Antibody drug conjugates
The present invention relates to anti-fgfr2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.. .
Oncostatin m receptor antigen binding proteins
The invention provides anti-oncostatin m receptor-β (osmr) antigen binding proteins, e.g., antibodies and functional fragments, derivatives, muteins, and variants thereof. Osmr antigen binding proteins interfere with binding of osm and/or il-31 to osmr.
Kiniksa Pharmaceuticals, Ltd.
Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
The present invention provides compositions and methods which involve specifically antagonizing gdf8 and activin a. In certain embodiments, compositions are provided which comprise a gdf8-specific binding protein and an activin a-specific binding protein.
Regeneron Pharmaceuticals, Inc.
Humanized beta-amyloid binding molecules and uses thereof
Provided herein are humanized antibodies or antigen-binding fragments thereof, that can bind to a cyclic peptide comprising the amino acid sequence snk, wherein the k (lysine) is solvent-accessible and methods of treating and/or preventing amyloid-beta associated diseases such as alzheimer's disease.. .
Cnj Holdings, Inc.
Monoclonal antibodies that modulate immunity to mtb and enhance immune clearance
The invention is directed to compositions and methods for stimulating, enhancing or modulating the immune system of a patient before or after infection by a pathogen, and in particular mtb. Compositions of the invention contain non-naturally occurring antigens that generate an effective cellular and/or humoral immune response to mtb and/or antibodies that are specifically reactive to mtb antigens.
Longhorn Vaccines And Diagnostics, Llc
Methods of treating and preventing staphylococcus aureus infections and associated conditions
The present invention relates to methods and compositions for preventing and treating staphylococcus aureus in a subject. Therapeutic compositions of the present invention comprise leukocidin e and/or d proteins or polypeptides and anti-leukocidin e and/or d antibodies.
New York University
Means and methods for producing stable antibodies
The invention provides means and methods for selecting and producing stable antibodies against an antigen of interest, using stable ex vivo b cell cultures.. .
Aimm Therapeutics B.v